Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANTELOPE in metastatic TTF-1-negative lung adenocarcinoma
2023-505054-17-00Phase 4Authorised
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Sep 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Non-small cell lung cancer adenocarcinoma (NSCLC) and non-small cell lung cancer (NSCLC) comparing Atezolizumab + carboplatin + nab-paclitaxel with Pembrolizumab + platinum + pemetrexed (2 arms). Primary endpoint: Overall survival. Planned start Sep 2023; status: authorised.
02
Drugs
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-505054-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505054-17-00.